Entries by Maren Kühr

MS expert takes the helm

Erik Lundgren assumed his role as the new CEO of Immunic. He succeeds Dr Daniel Vitt, who will continue to oversee the biotech company’s scientific strategy.

AI meets biotech: Europe’s new investival

Artificial intelligence is reshaping biotechnology, diagnostics and drug discovery. At the same time, Europe is competing globally for capital, talent and technological leadership. Bio:cap aims to strengthen this ecosystem by connecting investors, startups, researchers and policymakers in a new international investival in Berlin.

New CCO starts in June

Marc Clausse will take up his new role as Chief Commercial Officer at Santhera Pharmaceuticals (SIX: SANN) at the beginning of June. He succeeds Geert Jan van Daal, who is retiring.

Co-founder and CEO steps down

Dr Andrea Pfeifer, long-serving CEO and co-founder from AC Immune, has decided to retire. AC Immune’s Board of Directors has appointed the Chair, Dr Martin Zügel, to serve as interim CEO while the ongoing search for a permanent successor continues.

Professor Wallhäußer Innovation Award 2026

The 2026 Professor Wallhäußer Innovation Award was presented during this year’s PharmaCongress & PharmaTechnica 2026 at the end of March. First place went to AstraZeneca for the project “Automated Reading of Agar Plates for Environmental Monitoring with AI”.

,

Can Europe finance and keep its biotech winners?

The recent resurgence of life sciences IPOs in the US highlights a persistent ­structural imbalance: Europe generates world-class science but struggles to finance and retain it. The ­European Life Sciences Coalition was created to address this gap by mobilizing institutional ­capital and strengthening the policy framework needed to scale European innovation at home.